Uromigos-ASCO GU

Advertisement
The UromigosThe Uromigos | March 6, 2024
Reviewing the top presentations from ASCO GU 2024, including the phase III GETUG-AFU-18 study, CONTACT-02, and more.
Listen Now
The UromigosThe Uromigos | January 30, 2024
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
The UromigosThe Uromigos | January 30, 2024
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
The UromigosThe Uromigos | January 30, 2024
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
The UromigosThe Uromigos | January 30, 2024
Andrea Apolo, MD, discusses the phase III AMBASSADOR study that investigated adjuvant pembrolizumab against observation.
The UromigosThe Uromigos | January 30, 2024
Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024.
The UromigosThe Uromigos | January 30, 2024
Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer.
The UromigosThe Uromigos | January 30, 2024
Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer. ...
The UromigosThe Uromigos | January 30, 2024
The Uromigos discuss the presentations to look out for at this year's ASCO Genitourinary Cancers Symposium.
The UromigosThe Uromigos | August 1, 2023
Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium.
The UromigosThe Uromigos | August 1, 2023
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
The UromigosThe Uromigos | August 1, 2023
Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.
The UromigosThe Uromigos | August 1, 2023
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
The UromigosThe Uromigos | August 1, 2023
Christian Kollmannsberger, MD, FRCPC, discusses his presentation on utilizing miR371 as a biomarker for germ cell tumors.
The UromigosThe Uromigos | August 1, 2023
Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC.
The UromigosThe Uromigos | August 1, 2023
Michael Morris, MD discusses PARP inhibition for castration-resistant prostate cancer and the differing opinions on its use.
The UromigosThe Uromigos | August 1, 2023
Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the IMvigor130 study.
The UromigosThe Uromigos | August 1, 2023
Andrea Necchi, MD describes the results of the phase 2 KEYNOTE-057 study at the 2023 ASCO GU Cancers Symposium.
The UromigosThe Uromigos | November 11, 2022
Axel Bex, MD, PhD, from the Netherlands Cancer Institute, Amsterdam, described results of the NeoAvAx trial as ...
The UromigosThe Uromigos | November 11, 2022
Dr. Fred Saad describes the results of the PROpel Phase III trial.
Advertisement
Advertisement
Advertisement